Metabolic mapping of the effects of win 55212-2 intravenous administration in the rat

Francesco E. Pontieri, Giuseppe Conti, Alessandro Zocchi, Cesare Fieschi, Francesco Orzi

Research output: Contribution to journalArticlepeer-review

Abstract

The [14C]2-deoxyglucose method was applied to measure the effects of the synthetic cannabinoid agonist WIN 55212-2 intravenous administration on glucose utilization in the rat brain. Two doses of the drug, that have been reported previously to increase extracellular dopamine concentrations in the shell of the nucleus accumbens, were used (0.15-0.30 mg/kg). At the lower dose, WIN 55212-2 increased energy metabolism selectively in the accumbens shell. Conversely, the higher dose of the drug reduced glucose utilization in the hippocampal formation and ventromedial thalamic nucleus without affecting energy metabolism in the accumbens shell. These results may be useful to further understanding the addictive potentials of cannabinoid drugs.

Original languageEnglish
Pages (from-to)773-776
Number of pages4
JournalNeuropsychopharmacology
Volume21
Issue number6
DOIs
Publication statusPublished - Dec 1999

Keywords

  • Cannabinoids
  • Deoxyglucose
  • Drug abuse
  • Hippocampus
  • Nucleus accumbens
  • Shell
  • WIN 55212-2

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Metabolic mapping of the effects of win 55212-2 intravenous administration in the rat'. Together they form a unique fingerprint.

Cite this